RWD Shows Treatment Effectiveness with 30,000 Patients
19 September 2019
- Swedish researchers investigated whether there were any clinically meaningful differences between anti-psychotic medications’ effectiveness in treating schizophrenia
- A RWD database was used to carry out the nationwide study
- RWE allowed the study to find the treatments most likely to prevent relapses
Click here to see the source article
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at firstname.lastname@example.org